



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

				Complete if Known
Application Number	10/071411			
Filing Date	February 7, 2002			
First Named Inventor	Barnes, Glenn			
Art Unit	1637			
Examiner Name	Wilder, Cynthia B.			
Sheet	2	of	3	Attorney Docket Number
				MRI-021

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CW	B1	Hoshiko, S. et al. "Characterization of the human 5-lipoxygenase gene promoter." <i>Proc. Natl. Acad. Sci. USA</i> 87(23):9073-7 (1990).	
CW	B2	In, K.H. et al. "Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription." <i>J. Clin. Invest.</i> 99(5):1130-7 (1997).	
CW	B3	Israel, E. et al. "The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma." <i>Annals of Internal Medicine</i> 119(11):1059-66 (1993).	
CW	B4	Jatakanon, A. et al. "Changes in sputum eosinophils predict loss of asthma control." <i>Am. J. Respir. Crit. Care Med.</i> 161(1):64-72 (2000).	
CW	B5	Khachigian, L.M. et al. "Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells." <i>The Journal of Biological Chemistry</i> 270(46):27679-86 (1995).	
CW	B6	Li, L. et al. "Positive regulation of human α1(I) collagen promoter activity by transcription factor Sp1." <i>Gene</i> 164(2):229-34 (1995).	
CW	B7	Lönnqvist, K. et al. "Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal." <i>J. Allergy Clin. Immunol.</i> 107(5):812-7 (2001).	
CW	B8	Matsumoto, T. et al. "Molecular cloning and amino acid sequence of human 5-lipoxygenase." <i>Proc. Natl. Acad. Sci. USA</i> 85(1):26-30 (1988).	
CW	B9	Matsumoto, T. et al. "Correction to Proc. Natl. Acad. Sci. USA 85(1):26-30 (1988)." <i>Proc. Natl. Acad. Sci. USA</i> 85(10):3406 (1988).	
CW	B10	Moffitt, J.E. et al. "Management of asthma in children." <i>American Family Physician</i> 50(5):1039-50, 1053-5 (1994).	
CW	B11	O'Byrne, P.M. "Leukotrienes in the pathogenesis of asthma." <i>Chest</i> 111(2 Suppl):27S-34S (1997).	
CW	B12	Persson, M.G. et al. "Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits." <i>Anesthesiology</i> 82(4):969-74 (1995).	
CW	B13	Powell, W.S. et al. "Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis." <i>J. Allergy Clin. Immunol.</i> 107(2):272-8 (2001).	
CW	B14	Samuelsson, B. "Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation." <i>Science</i> 220(4597):568-75 (1983).	
CW	B15	Samuelsson, B. et al. "Leukotrienes and lipoxins: structures, biosynthesis, and biological effects." <i>Science</i> 237(4819):1171-6 (1987).	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature

Cynthia Wilder

Date Considered

5/18/2004